探讨套细胞淋巴瘤（MCL）外周血T淋巴细胞亚群与总生存期（OS）及临床基线特征的相关性。山西医科第二医院血液科55例初诊MCL患者的临床资料对2012年1月至2022年7月的大学进行回顾性分析。采用流式细胞术检测外周血T淋巴细胞亚群百分比及CD4/CD8比值，并分析其与患者临床特征的相关性。采用Kaplan-Meier法进行生存分析并绘制生存曲线。单因素分析采用Log-rank检验，多因素分析采用Cox比例风险模型。中位随访时间为40(1-68)个月，中位总生存期(OS)为47个月。 55例患者中，30例（54.5%）患者外周血CD4 T淋巴细胞降低，17例（30.9%）患者外周血CD8 T淋巴细胞升高，20例（36.4%）患者CD4下降/CD8 比率。 CD4/CD8比值与性别、年龄、Ki-67、B症状、白细胞、血红蛋白、淋巴细胞、血小板、白蛋白、乳酸脱氢酶(LDH)、β2-微球蛋白、脾肿大、骨髓侵犯、原发部位无显着相关性和 MIPI 分数。生存分析显示，CD4 T细胞>23.3%、CD8 T细胞≤33.4%、CD4/CD8比值>0.6的患者OS较长（P=0.020、P<0.001、P<0.001）。单因素分析显示Ki-67>30%、LDH>250 U/L、脾肿大、骨髓受累、CD4 T细胞≤23.3%、CD8 T细胞>33.4%、CD4/CD8比值≤0.6为影响OS的不良预后因素MCL 患者。多因素分析显示CD4/CD8比值≤0.6（HR=4.382，P=0.005）是MCL患者OS的独立不良预后因素。CD4/CD8比值低与MCL预后不良相关，CD4/CD8比值低与MCL患者预后不良相关。可作为评估MCL患者预后风险的重要指标。

To investigate the correlation of peripheral blood T lymphocyte subsets with overall survival (OS) and clinical baseline characteristics in mantle cell lymphoma (MCL).The clinical data of 55 MCL patients who were newly diagnosed in the Department of Hematology, Second Hospital of Shanxi Medical University from January 2012 to July 2022 were analyzed retrospectively. The percentages of T lymphocyte subsets and CD4+/CD8+ ratio in peripheral blood were detected by flow cytometry, and their correlation with clinical characteristics of patients were analyzed. Kaplan-Meier method was used for survival analysis and survival curves were drawn. Log-rank test was used for univariate analysis, while Cox proportional hazards model was used for multivariate analysis.The median follow-up was 40(1-68) months, and the median overall survival (OS) was 47 months. Among the 55 patients, 30(54.5%) patients had a decrease in peripheral blood CD4+T lymphocyte, while 17(30.9%) patients had a increase in peripheral blood CD8+T lymphocyte, and 20(36.4%) patients had a decrease in CD4+/CD8+ ratio. There were no significant correlations between CD4+/CD8+ ratio and sex, age, Ki-67, B symptoms, leukocytes, hemoglobin, lymphocytes, platelets, albumin, lactate dehydrogenase (LDH), β2-microglobulin, splenomegaly, bone marrow invasion, primary site and MIPI score. Survival analysis showed that patients with CD4+T cell >23.3%, CD8+T cell ≤33.4% and CD4+/CD8+ ratio >0.6 had longer OS (P =0.020, P <0.001, P <0.001). Univariate analysis showed that Ki-67>30%, LDH>250 U/L, splenomegaly, bone marrow involvement, CD4+T cells ≤23.3%, CD8+ T cells >33.4%, CD4+/CD8+ ratio ≤0.6 were adverse prognostic factors affecting OS of MCL patients. Multivariate analysis showed that CD4+/CD8+ ratio ≤0.6 (HR =4.382, P =0.005) was an independent adverse prognostic factor for OS of MCL patients.Low CD4+/CD8+ ratio is associated with poor prognosis in MCL, and the CD4+/CD8+ ratio can be used as an important indicator to evaluate the prognosis risk in MCL patients.